The different clinical presentations dependent on JAK2 mutations of PV, ET, and MF could be partially explained by the different allele burden of JAK2; for example, when a high JAK2-V617F allele burden is expressed, the disease shows a more aggressive behaviour [26]. This evidence concerns the gene JAK2 and essential thrombocythemia.